Search Results for:

October 2022

Second clinical study announced, evaluating QRX003 in Netherton Syndrome patients receiving off-label systemic therapy.

First

QUT

Endo

Orpharm

Genpharm

Neopharm

OrphanDC

WinHealth

Er-Kim